Gregory Huhn is an Infectious Disease physician affiliated with Ruth M. Rothstein CORE Center. OpenAlex indexes 89 publications with 6,753 citations (h-index 26); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2020 W Harrison St
Chicago, IL 606123741
Telephone
312-572-4575Provider last certified this registry record 26 Apr 2021.
Clinical trials
- Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy
Sponsor: Ruth M. Rothstein CORE Center
- DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects
Sponsor: Ruth M. Rothstein CORE Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20244 payments
- Gilead Sciences, Inc.Program year20242 payments
- Valneva Usa, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
46.8%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor23.4%Cabenuva65%Tivicay24%Dovato12%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor8.7%Descovy86%Emtricitabine14%Part D<11 patients+ 6 more classes in this area
Cardiovascular
18.4%Statin9%Atorvastatin Calcium77%Rosuvastatin Calcium23%Part D<11 patientsACE inhibitor5.8%Enalapril Maleate100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
12.4%Biguanide (metformin)4.3%Metformin Hcl100%Part D<11 patientsSGLT2 inhibitor2%Jardiance100%Part D<11 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2016–2019 per NIH RePORTER. The latest:
- Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM
Hektoen Institute for Medical Research
FY2019$286,554R01AI122308 - Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM
Hektoen Institute for Medical Research
FY2018$423,781R01AI122308 - Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM
Hektoen Institute for Medical Research
FY2017$624,203R01AI122308
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Excess Weight Gain With Integrase Inhibitors and Tenofovir Alafenamide: What Is the Mechanism and Does It Matter?
Open Forum Infectious Diseases
2021 - A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
Infectious Diseases and Therapy
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”